ROBERT M. JONES,JUERG LEHMANN,WEICHAO CHEN,JEFFREY EDWARDS,GLEN MARQUEZ,ABU J.M. SADEQUE,SUN HEE KIM
申请号：
DO2013000061
公开号：
DOP2013000061A
申请日:
2013.03.21
申请国别(地区):
DO
年份:
2013
代理人:
摘要：
The present Invention relates to GPR119 receptor agonists: 3-fluoro-4 - (4-fluoro-6 - 5 - (4 - (3 - (2 - fluoropropan - 2 - il) - 1,2,4 - Oxadiazoles - 5 - il) piperidin-1-yl) - 4 - ilamino pyrimidin-2-yl) - n, n-dimethylbenzamide； 3 - 4 - 5 - fluoro - (4-fluoro-6 - (4 - (3 - (2 - fluoropropan - 2 - il) - 1,2,4 - Oxadiazoles - 5 - il) piperidin-1-yl) - pyrimidin-2-yl 4 - ilamino) - n-methylbenzamide and 3 - 4 - 5 - fluoro - (4-fluoro-6 - (4 - (3 - (2 - fluoropropan - 2 - 1.2, - il)Oxadiazoles - 4 - 5 - il) piperidin-1-yl) pyrimidin-2-yl) - 4 - ilamino benzamide, and pharmaceutically acceptable salts, solvates and hydrates thereof, which are useful as a Pharmaceutical Agent only or combined with one or more additional Pharmaceutical agents such as a dpp-iv Inhibitor, a Biguanide An inhibitor of alpha Glucosidase, an insulin Analogue, a sulfonylurea, an inhibitor of sglt2,A tiazolidinodiona meglitinide Analogue, Peptide, or an Antidiabetic Agent, in the treatment of, for example, a disorder selected from: a GPR119 receptor related Disorder, a condition improved by increasing the secretion of an incretin, a condition improved the incr Enter the incretin levels in the Blood, a condition characterized by Low bone mass,A Neurological Disorder, a disorder related to metabolism, Type 2 diabetes, Obesity and related complications.La presente invención se refiere a los agonistas del receptor GPR119: 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-il)-1,2,4-oxadiazol-5-il)piperidin-1-il)pirimidin-4-ilamino)-N,N-dimetilbenzamida； 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-il)-1,2,4-oxadiazol-5-il)piperidin-1-il)pirimidin-4-ilamino)-N-metilbenzamida； y 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-il)-1,2,4-oxadiazol-5-il)piperidin-1-il)pirimidin-4-ilamino)benzamida, y a sales, solvatos e hidratos farmacéuticamente aceptables de estos, que son útiles como un agente farmacéutico único o combinados con uno o más agentes farmacéuticos adicionales tales como un inhibidor de DPP-
